


PHARMACEUTICAL 2020

Rezolute Inc. Rank 340 of 362





PHARMACEUTICAL 2020

Rezolute Inc. Rank 340 of 362

The relative strengths and weaknesses of Rezolute Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rezolute Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Rezolute Inc. is the variable Net Income, reducing the Economic Capital Ratio by 571% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,070%, being 767% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	12,144
Cost of Goods Sold	0
Intangible Assets	29
Liabilities, Current	8,379
Liabilities, Non-Current	121
Other Assets	35
Other Compr. Net Income	0
Other Expenses	45
Other Liabilities	2,000
Other Net Income	-4,502
Property and Equipment	44
Research and Development	19,079
Revenues	0
Selling, General and Administrative Expense	6,820

Output Variable	Value in 1000 USD
Assets	12,252
Liabilities	10,500
Expenses	25,944
Stockholders Equity	1,752
Net Income	-30,446
Comprehensive Net Income	-30,446
Economic Capital Ratio	-1,070%